Jules Victor, MD
Internal Medicine · Savannah, GANPI 1306845029
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 223 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 14.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $788, 2.2 times the $352 reported in 2019.
Across 223 payments — averaging $17.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$554
- Novo Nordisk$470
- Lilly USA, LLC$424
- AbbVie$357
- Amgen$263
- Viiv Healthcare Company$261
- plus $1K from 32 others
What the payments were for
- Food & beverage$3,816100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 33 | $554 |
| Novo Nordisk | 32 | $470 |
| Lilly USA, LLC | 24 | $424 |
| AbbVie(2 entities) | 18 | $357 |
| Amgen | 18 | $263 |
| Viiv Healthcare Company | 11 | $261 |
| Boehringer Ingelheim | 7 | $143 |
| Merck | 8 | $140 |
| Pfizer | 8 | $135 |
| Dexcom, Inc. | 8 | $126 |
| Bayer | 6 | $102 |
| Esperion Therapeutics, Inc. | 5 | $76 |
| AstraZeneca | 4 | $67 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $61 |
| Lundbeck LLC | 3 | $50 |
| Exact Sciences | 3 | $49 |
| Eisai Inc. | 3 | $48 |
| Mannkind Corporation | 2 | $46 |
| Axsome Therapeutics, Inc. | 2 | $42 |
| Astellas Pharma US Inc | 2 | $37 |
| Idorsia Pharmaceuticals US Inc | 2 | $36 |
| Paratek Pharmaceuticals, Inc. | 2 | $33 |
| Kowa Pharmaceuticals America, Inc. | 2 | $32 |
| Phathom Pharmaceuticals, Inc. | 2 | $27 |
| Abiomed | 1 | $25 |
| Shionogi Inc | 1 | $25 |
| Edwards Lifesciences | 1 | $24 |
| Ferring Pharmaceuticals Inc. | 1 | $19 |
| Aimmune Therapeutics, Inc. | 1 | $19 |
| Shire North American Group Inc | 1 | $18 |
| Sunovion Pharmaceuticals Inc. | 1 | $17 |
| Medtronic | 1 | $15 |
| Endo Pharmaceuticals Inc. | 1 | $13 |
| Abbott | 1 | $13 |
| Currax Pharmaceuticals LLC | 1 | $13 |
| Amarin Pharma, Inc. | 1 | $13 |
| Galderma Laboratories, L.p. | 1 | $13 |
| EMD Serono, Inc. | 1 | $11 |
How this compares
$3,816 in reported general payments places this provider in the 85th percentile of 3,311 internal medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 50 | $48,068 |
| MounjaroTirzepatide | 35 | $43,540 |
| FarxigaDapagliflozin Propanediol | 35 | $40,253 |
| JardianceEmpagliflozin | 35 | $39,142 |
| EliquisApixaban | 30 | $21,048 |
| MyrbetriqMirabegron | 22 | $17,807 |
| OzempicSemaglutide | 17 | $17,024 |
| Repatha SureclickEvolocumab | 14 | $16,894 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 11 | $16,352 |
| JanumetSitagliptin Phos/Metformin Hcl | 13 | $15,648 |
| FiaspInsulin Aspart (Niacinamide) | 14 | $12,128 |
| EdarbiAzilsartan Medoxomil | 11 | $10,431 |
| VascepaIcosapent Ethyl | 13 | $9,998 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 11 | $7,498 |
| Rosuvastatin Calcium | 506 | $6,645 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia, Janumet Xr, Janumet | $140 | $80,06874 claims |
| Lilly USA, LLCMounjaro | $424 | $43,54035 claims |
| AstraZenecaFarxiga | $67 | $40,25335 claims |
| Boehringer IngelheimJardiance | $143 | $39,14235 claims |
| Novo NordiskOzempic, Fiasp | $470 | $29,15231 claims |
| PfizerEliquis, Paxlovid | $135 | $22,47752 claims |
| Astellas Pharma US IncMyrbetriq | $37 | $17,80722 claims |
| AbbVieSynthroid | $357 | $3,27034 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,311 internal medicine providers in Georgia.
Other internal medicine in Savannah
- Jennifer WoehlerSavannah$207K
- Timothy ConnellySavannah$50K
- John DemiccoSavannah$31K
- Paul BradleySavannah$28K
- Wilfredo DolorSavannah$17K
- Thomas HoganSavannah$17K
- Thomas MoriaritySavannah$16K
- Michael GibsonSmyrna$2.2M
- Eduard FatakhovAlpharetta$376K
- Tracey HenryAtlanta$305K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.